疫苗诱导黑猩猩抵抗慢性丙型肝炎病毒感染的免疫机制。
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.
作者信息
Verstrepen Babs E, Boonstra André, Koopman Gerrit
机构信息
Babs E Verstrepen, Gerrit Koopman, Department of Virology, Biomedical Primate Research Centre, 2280GH Rijswijk, The Netherlands.
出版信息
World J Hepatol. 2015 Jan 27;7(1):53-69. doi: 10.4254/wjh.v7.i1.53.
Abstract
Hepatitis C virus (HCV) infection is characterized by a high propensity for development of life-long viral persistence. An estimated 170 million people suffer from chronic hepatitis caused by HCV. Currently, there is no approved prophylactic HCV vaccine available. With the near disappearance of the most relevant animal model for HCV, the chimpanzee, we review the progression that has been made regarding prophylactic vaccine development against HCV. We describe the results of the individual vaccine evaluation experiments in chimpanzees, in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved, but a clear correlate of protection has thus far not yet been defined.
摘要
丙型肝炎病毒（HCV）感染的特点是极易形成终身病毒持续性感染。据估计，有1.7亿人患有由HCV引起的慢性肝炎。目前，尚无获批的预防性HCV疫苗。随着HCV最相关的动物模型黑猩猩几近消失，我们回顾了在HCV预防性疫苗研发方面取得的进展。我们描述了在黑猩猩身上进行的个体疫苗评估实验结果，并与在人类身上观察到的情况进行了对比。不同研究的结果表明，可以实现对感染的部分保护，但迄今为止尚未明确保护的明确关联因素。
相似文献
1
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.疫苗诱导黑猩猩抵抗慢性丙型肝炎病毒感染的免疫机制。
World J Hepatol. 2015 Jan 27;7(1):53-69. doi: 10.4254/wjh.v7.i1.53.
2
Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.E2 高变区 (HVR1) 在重组丙型肝炎病毒疫苗免疫原性中的作用。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.02141-17. Print 2018 Jun 1.
3
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.用编码丙型肝炎病毒（HCV）包膜E2蛋白的质粒DNA对黑猩猩进行疫苗接种，改变了同源单克隆HCV攻击后的感染情况。
Hepatology. 2000 Sep;32(3):618-25. doi: 10.1053/jhep.2000.9877.
4
Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.黑猩猩体内丙型肝炎病毒的研究及其对疫苗研发的重要性。
Intervirology. 2001;44(2-3):132-42. doi: 10.1159/000050040.
5
Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.开发一种针对丙型肝炎病毒感染的异源多基因型疫苗。
Eur J Clin Invest. 2007 May;37(5):396-406. doi: 10.1111/j.1365-2362.2007.01802.x.
6
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.预防性和治疗性丙型肝炎病毒 (HCV) 疫苗接种：发展与未来展望。
Viruses. 2009 Sep;1(2):144-65. doi: 10.3390/v1020144. Epub 2009 Aug 12.
7
Perspectives for a hepatitis C virus vaccine.丙型肝炎病毒疫苗的前景。
Clin Diagn Virol. 1998 Jul 15;10(2-3):181-5. doi: 10.1016/s0928-0197(98)00028-2.
8
Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.DNA 启动的 RNA 复制子和改良安卡拉痘苗病毒 HCV 疫苗接种诱导小鼠产生强效抗丙型肝炎病毒 (HCV) T 细胞免疫应答。
J Virol. 2019 Mar 21;93(7). doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.
9
Ever closer to a prophylactic vaccine for HCV.越来越接近丙型肝炎预防性疫苗。
Expert Opin Biol Ther. 2013 Aug;13(8):1109-24. doi: 10.1517/14712598.2013.791277. Epub 2013 May 7.
10
Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.重组丙型肝炎病毒包膜糖蛋白疫苗可引发针对包膜糖蛋白上多个表位的抗体，这些表位与广泛的交叉中和作用相关。
J Virol. 2014 Dec;88(24):14278-88. doi: 10.1128/JVI.01911-14. Epub 2014 Oct 1.
引用本文的文献
1
Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.丙型肝炎病毒抗体相关E2糖蛋白的反向表位作图
PLoS One. 2017 May 30;12(5):e0175349. doi: 10.1371/journal.pone.0175349. eCollection 2017.
2
Immune protection against reinfection with nonprimate hepacivirus.抗非灵长类肝炎病毒再感染的免疫保护。
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2430-E2439. doi: 10.1073/pnas.1619380114. Epub 2017 Mar 8.
3
The Strange, Expanding World of Animal Hepaciviruses.动物庚型肝炎病毒的奇异世界不断扩大。
Annu Rev Virol. 2016 Sep 29;3(1):53-75. doi: 10.1146/annurev-virology-100114-055104.
4
T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.非人灵长类动物中针对丙型肝炎病毒的多价初免-加强DNA和病毒载体疫苗组合的T细胞和B细胞反应。
Gene Ther. 2016 Oct;23(10):753-759. doi: 10.1038/gt.2016.55. Epub 2016 Jul 14.
本文引用的文献
1
Treatment of hepatitis C: a systematic review.丙型肝炎的治疗：系统评价。
JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085.
2
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.开发能引发中和抗体的丙型肝炎病毒疫苗所面临的挑战。
Front Microbiol. 2014 Jul 3;5:329. doi: 10.3389/fmicb.2014.00329. eCollection 2014.
3
Efficacy of daclatasvir in hepatitis C virus.达卡他韦治疗丙型肝炎病毒的疗效
Expert Rev Anti Infect Ther. 2014 Sep;12(9):1025-31. doi: 10.1586/14787210.2014.942282. Epub 2014 Jul 25.
4
Trace amounts of sporadically reappearing HCV RNA can cause infection.偶尔再次出现的痕量丙型肝炎病毒核糖核酸（HCV RNA）可导致感染。
J Clin Invest. 2014 Aug;124(8):3469-78. doi: 10.1172/JCI73104. Epub 2014 Jul 8.
5
Protective immunity against hepatitis C: many shades of gray.针对丙型肝炎的保护性免疫：诸多灰色地带。
Front Immunol. 2014 Jun 16;5:274. doi: 10.3389/fimmu.2014.00274. eCollection 2014.
6
Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?慢性乙型和丙型肝炎感染中的抑制性受体分子：免疫治疗的新靶点？
Rev Med Virol. 2014 Mar;24(2):125-38. doi: 10.1002/rmv.1779.
7
Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection.在清除丙型肝炎病毒感染的黑猩猩中，强效疫苗诱导的CD8 T细胞反应具有细胞溶解功能。
PLoS One. 2014 Apr 16;9(4):e95103. doi: 10.1371/journal.pone.0095103. eCollection 2014.
8
Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude.I型和III型干扰素诱导的免疫反应：这是一个动力学和强度的问题。
Hepatology. 2014 Apr;59(4):1225-8. doi: 10.1002/hep.26959. Epub 2014 Feb 28.
9
Confronting the emerging epidemic of HCV infection among young injection drug users.应对年轻注射吸毒者中丙型肝炎病毒感染的新出现流行。
Am J Public Health. 2014 May;104(5):816-21. doi: 10.2105/AJPH.2013.301812. Epub 2014 Mar 13.
10
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.基于特拉匹韦或博赛匹韦的慢性丙型肝炎感染治疗：治疗失败时耐药相关变异体的出现。
Antiviral Res. 2014 May;105:112-7. doi: 10.1016/j.antiviral.2014.02.019. Epub 2014 Mar 1.
Zotero 插件